Kasey McFarling
Family · Midlothian, VANPI 1780925008
Payments from drug & device makers
Across 454 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- AstraZeneca$2K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$481
- Novartis$419
- Amgen$417
- plus $4K from 31 others
What the payments were for
- Travel & lodging$98710%
- Food & beverage$8,79088%
- Education$1952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 35 | $2,115 |
| AstraZeneca | 71 | $1,722 |
| GSK | 95 | $1,275 |
| Regeneron Healthcare Solutions, Inc. | 20 | $481 |
| Novartis | 25 | $419 |
| Amgen | 25 | $417 |
| Sanofi | 20 | $372 |
| Mylan Specialty L.p. | 24 | $371 |
| Boehringer Ingelheim | 16 | $334 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $297 |
| Paratek Pharmaceuticals, Inc. | 18 | $293 |
| Insmed, Inc. | 15 | $282 |
| Genentech USA, Inc. | 16 | $206 |
| Harmony Biosciences LLC | 7 | $172 |
| Actelion Pharmaceuticals US, Inc. | 4 | $167 |
| Grifols USA, LLC | 7 | $131 |
| United Therapeutics Corporation | 5 | $109 |
| Jazz Pharmaceuticals Inc. | 6 | $101 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Mallinckrodt Hospital Products Inc. | 4 | $91 |
| Electromed, Inc. | 6 | $78 |
| Vifor Pharma, Inc. | 2 | $50 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| AbbVie | 2 | $44 |
| Philips North America LLC | 3 | $44 |
| ANI Pharmaceuticals, Inc. | 2 | $42 |
| Atricure, Inc. | 1 | $34 |
| Johnson & Johnson | 1 | $32 |
| Astellas Pharma US Inc | 1 | $19 |
| Resmed Corp | 1 | $17 |
| Merck | 1 | $17 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $17 |
| Inogen, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Pfizer | 1 | $16 |
| Verona Pharma, Inc. | 1 | $16 |
| Viatris Specialty LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,972 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 218 | $173,045 |
| Dupixent PenDupilumab | 12 | $50,826 |
| Dupixent SyringeDupilumab | 14 | $48,879 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $36,743 |
| Spiriva RespimatTiotropium Bromide | 43 | $28,015 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $17,115 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $8,921 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $8,463 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $6,885 |
| XareltoRivaroxaban | 12 | $6,505 |
| DuleraMometasone/Formoterol | 11 | $4,189 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,733 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 154 | $3,600 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $2,373 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,275 | $199,082271 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,722 | $43,62869 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $334 | $36,47857 claims |
| Johnson & JohnsonXarelto | $32 | $6,50512 claims |
| MerckDulera | $17 | $4,18911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Midlothian
- Sean OlaughlinMidlothian$110K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.